StockNews.com Begins Coverage on ChromaDex (NASDAQ:CDXC)

Research analysts at StockNews.com started coverage on shares of ChromaDex (NASDAQ:CDXC) in a report issued on Friday. The firm set a “buy” rating on the stock.

A number of other analysts have also issued reports on the company. LADENBURG THALM/SH SH boosted their price target on ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a report on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of ChromaDex in a report on Monday, March 17th.

ChromaDex Stock Performance

The stock has a market cap of $611.50 million, a PE ratio of 787.29 and a beta of 2.21. The firm has a 50-day moving average of $6.16 and a 200-day moving average of $5.44. ChromaDex has a 52-week low of $2.31 and a 52-week high of $9.18.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CDXC. Geode Capital Management LLC lifted its holdings in ChromaDex by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,154,778 shares of the company’s stock valued at $6,128,000 after purchasing an additional 5,186 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its stake in shares of ChromaDex by 1,785.9% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company’s stock worth $5,365,000 after buying an additional 957,665 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of ChromaDex by 68.0% in the fourth quarter. Renaissance Technologies LLC now owns 712,788 shares of the company’s stock worth $3,781,000 after buying an additional 288,588 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in ChromaDex by 288.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 662,956 shares of the company’s stock worth $3,517,000 after acquiring an additional 492,148 shares during the last quarter. Finally, State Street Corp raised its holdings in ChromaDex by 11.3% in the 3rd quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after acquiring an additional 62,692 shares during the last quarter. Institutional investors and hedge funds own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.